poeder voor injectievloeistof

DRUG2 trials

Sponsors

Amsterdam UMC Stichting, Crinetics Pharmaceuticals Inc.

Conditions

Pancreatic conditions requiring pancreaticoduodenectomysuch as pancreatic head carcinoma or intraductal papillary mucinous neoplasms (IPMN).• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent Cushing´s syndrome.

Phase 2

A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)

Not yet recruitingCTIS2025-522648-42-01

Crinetics Pharmaceuticals Inc.• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent Cushing´s syndrome.

Target: 25Updated: 2026-09-29

Phase 4

Preventing postoperative complications in patients undergoing high-risk pancreatoduodenectomy with a bundle approach including hydrocortisone, ocreotide, and teres ligament patch (PANENCA): an international randomized controlled multicenter trial

RecruitingCTIS2024-519667-18-00

Amsterdam UMC StichtingPancreatic conditions requiring pancreaticoduodenectomy, such as pancreatic head carcinoma or intraductal papillary mucinous neoplasms (IPMN).

Start: 2025-08-21Target: 400Updated: 2025-10-29